Donald McAlpine, MD
Pulmonary Disease · Cape Coral, FLNPI 1154329183
Payments from drug & device makers
Across 692 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$2K
- GSK$2K
- Grifols USA, LLC$1K
- Boehringer Ingelheim$1K
- Actelion Pharmaceuticals US, Inc.$1K
- plus $6K from 50 others
What the payments were for
- Travel & lodging$3442%
- Food & beverage$12,78978%
- Education$3,32720%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- AIRSUPRA$278
- BREZTRI$278
- Da Vinci Surgical System$242
- FASENRA$149
- TEZSPIRE$149
- TYVASO$134
- TRELEGY ELLIPTA$120
How this compares
$16,461 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 60 | $781,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 734 | $738,005 |
| UptraviSelexipag | 11 | $246,551 |
| OpsumitMacitentan | 15 | $192,182 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 200 | $182,697 |
| Breo ElliptaFluticasone/Vilanterol | 208 | $130,854 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $53,001 |
| Ambrisentan | 25 | $52,430 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $46,725 |
| SymbicortBudesonide/Formoterol Fumarate | 97 | $40,790 |
| EliquisApixaban | 34 | $36,245 |
| Spiriva RespimatTiotropium Bromide | 35 | $32,334 |
| XareltoRivaroxaban | 24 | $19,925 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 618 | $17,660 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 134 | $17,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,545 | $923,6601,020 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,268 | $877,894174 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,016 | $438,73226 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,991 | $223,487297 claims |
| Johnson & JohnsonXarelto | $159 | $19,92524 claims |
| MerckDulera, Asmanex | $451 | $12,00737 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $15 | $4,37414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Cape Coral
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.